Cargando…

Factors associated with development of nephrotoxicity in patients treated with vancomycin versus daptomycin for severe Gram-positive infections: A practice-based study

OBJECTIVES: To evaluate nephrotoxicity development in patients treated with vancomycin (VAN) and daptomycin (DAP) for proven severe Gram-positive infections in daily practice. PATIENTS AND METHODS: A practice-based, observational, retrospective study (eight Spanish hospitals) was performed including...

Descripción completa

Detalles Bibliográficos
Autores principales: Barberán, José, Mensa, José, Artero, Arturo, Epelde, Francisco, Rodriguez, Juan-Carlos, Ruiz-Morales, Josefa, Calleja, José-Luis, Guerra, José-Manuel, Martínez-Gil, Iñigo, Giménez, María-José, Granizo, Juan-José, Aguilar, Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedad Española de Quimioterapia 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372966/
https://www.ncbi.nlm.nih.gov/pubmed/30630306
_version_ 1783394871121281024
author Barberán, José
Mensa, José
Artero, Arturo
Epelde, Francisco
Rodriguez, Juan-Carlos
Ruiz-Morales, Josefa
Calleja, José-Luis
Guerra, José-Manuel
Martínez-Gil, Iñigo
Giménez, María-José
Granizo, Juan-José
Aguilar, Lorenzo
author_facet Barberán, José
Mensa, José
Artero, Arturo
Epelde, Francisco
Rodriguez, Juan-Carlos
Ruiz-Morales, Josefa
Calleja, José-Luis
Guerra, José-Manuel
Martínez-Gil, Iñigo
Giménez, María-José
Granizo, Juan-José
Aguilar, Lorenzo
author_sort Barberán, José
collection PubMed
description OBJECTIVES: To evaluate nephrotoxicity development in patients treated with vancomycin (VAN) and daptomycin (DAP) for proven severe Gram-positive infections in daily practice. PATIENTS AND METHODS: A practice-based, observational, retrospective study (eight Spanish hospitals) was performed including patients ≥18 years with a baseline glomerular filtration rate (GFR)>30 mL/min and/or serum creatinine level<2 mg/dL treated with DAP or VAN for >48h. Nephrotoxicity was considered as a decrease in baseline GRF to <50 mL/min or decrease of >10 mL/min from a baseline GRF<50 mL/min. Multivariate analyses were performed to determine factors associated with 1) treatment selection, 2) nephrotoxicity development, and 3) nephrotoxicity development within each antibiotic group. RESULTS: A total of 133 patients (62 treated with DAP, 71 with VAN) were included. Twenty-one (15.8%) developed nephrotoxicity: 4/62 (6.3%) patients with DAP and 17/71 (23.3%) with VAN (p=0.006). No differences in concomitant administration of aminoglycosides or other potential nephrotoxic drugs were found between groups. Factors associated with DAP treatment were diabetes mellitus with organ lesion (OR=7.81, 95%CI:1.39-4.35) and basal creatinine ≥0.9 mg/dL (OR=2.53, 95%CI:1.15-4.35). Factors associated with VAN treatment were stroke (OR=7.22, 95%CI:1.50-34.67), acute myocardial infarction (OR=6.59, 95%CI:1.51-28.69) and primary bacteremia (OR=5.18, 95%CI:1.03-25.99). Factors associated with nephrotoxicity (R(2)=0.142; p=0.001) were creatinine clearance<80 mL/min (OR=9.22, 95%CI:1.98-30.93) and VAN treatment (OR=6.07, 95%CI:1.86-19.93). Factors associated with nephrotoxicity within patients treated with VAN (R(2)=0.232; p=0.018) were congestive heart failure (OR=4.35, 95%CI:1.23-15.37), endocarditis (OR=7.63, 95%CI:1.02-57.31) and basal creatinine clearance<80 mL/min (OR=7.73, 95%CI:1.20-49.71). CONCLUSIONS: Nephrotoxicity with VAN was significantly higher than with DAP despite poorer basal renal status in the DAP group.
format Online
Article
Text
id pubmed-6372966
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Sociedad Española de Quimioterapia
record_format MEDLINE/PubMed
spelling pubmed-63729662019-03-04 Factors associated with development of nephrotoxicity in patients treated with vancomycin versus daptomycin for severe Gram-positive infections: A practice-based study Barberán, José Mensa, José Artero, Arturo Epelde, Francisco Rodriguez, Juan-Carlos Ruiz-Morales, Josefa Calleja, José-Luis Guerra, José-Manuel Martínez-Gil, Iñigo Giménez, María-José Granizo, Juan-José Aguilar, Lorenzo Rev Esp Quimioter Original OBJECTIVES: To evaluate nephrotoxicity development in patients treated with vancomycin (VAN) and daptomycin (DAP) for proven severe Gram-positive infections in daily practice. PATIENTS AND METHODS: A practice-based, observational, retrospective study (eight Spanish hospitals) was performed including patients ≥18 years with a baseline glomerular filtration rate (GFR)>30 mL/min and/or serum creatinine level<2 mg/dL treated with DAP or VAN for >48h. Nephrotoxicity was considered as a decrease in baseline GRF to <50 mL/min or decrease of >10 mL/min from a baseline GRF<50 mL/min. Multivariate analyses were performed to determine factors associated with 1) treatment selection, 2) nephrotoxicity development, and 3) nephrotoxicity development within each antibiotic group. RESULTS: A total of 133 patients (62 treated with DAP, 71 with VAN) were included. Twenty-one (15.8%) developed nephrotoxicity: 4/62 (6.3%) patients with DAP and 17/71 (23.3%) with VAN (p=0.006). No differences in concomitant administration of aminoglycosides or other potential nephrotoxic drugs were found between groups. Factors associated with DAP treatment were diabetes mellitus with organ lesion (OR=7.81, 95%CI:1.39-4.35) and basal creatinine ≥0.9 mg/dL (OR=2.53, 95%CI:1.15-4.35). Factors associated with VAN treatment were stroke (OR=7.22, 95%CI:1.50-34.67), acute myocardial infarction (OR=6.59, 95%CI:1.51-28.69) and primary bacteremia (OR=5.18, 95%CI:1.03-25.99). Factors associated with nephrotoxicity (R(2)=0.142; p=0.001) were creatinine clearance<80 mL/min (OR=9.22, 95%CI:1.98-30.93) and VAN treatment (OR=6.07, 95%CI:1.86-19.93). Factors associated with nephrotoxicity within patients treated with VAN (R(2)=0.232; p=0.018) were congestive heart failure (OR=4.35, 95%CI:1.23-15.37), endocarditis (OR=7.63, 95%CI:1.02-57.31) and basal creatinine clearance<80 mL/min (OR=7.73, 95%CI:1.20-49.71). CONCLUSIONS: Nephrotoxicity with VAN was significantly higher than with DAP despite poorer basal renal status in the DAP group. Sociedad Española de Quimioterapia 2019-02-08 2019-02 /pmc/articles/PMC6372966/ /pubmed/30630306 Text en © The Author 2019 https://creativecommons.org/licenses/by-nc/4.0/ The article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle Original
Barberán, José
Mensa, José
Artero, Arturo
Epelde, Francisco
Rodriguez, Juan-Carlos
Ruiz-Morales, Josefa
Calleja, José-Luis
Guerra, José-Manuel
Martínez-Gil, Iñigo
Giménez, María-José
Granizo, Juan-José
Aguilar, Lorenzo
Factors associated with development of nephrotoxicity in patients treated with vancomycin versus daptomycin for severe Gram-positive infections: A practice-based study
title Factors associated with development of nephrotoxicity in patients treated with vancomycin versus daptomycin for severe Gram-positive infections: A practice-based study
title_full Factors associated with development of nephrotoxicity in patients treated with vancomycin versus daptomycin for severe Gram-positive infections: A practice-based study
title_fullStr Factors associated with development of nephrotoxicity in patients treated with vancomycin versus daptomycin for severe Gram-positive infections: A practice-based study
title_full_unstemmed Factors associated with development of nephrotoxicity in patients treated with vancomycin versus daptomycin for severe Gram-positive infections: A practice-based study
title_short Factors associated with development of nephrotoxicity in patients treated with vancomycin versus daptomycin for severe Gram-positive infections: A practice-based study
title_sort factors associated with development of nephrotoxicity in patients treated with vancomycin versus daptomycin for severe gram-positive infections: a practice-based study
topic Original
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372966/
https://www.ncbi.nlm.nih.gov/pubmed/30630306
work_keys_str_mv AT barberanjose factorsassociatedwithdevelopmentofnephrotoxicityinpatientstreatedwithvancomycinversusdaptomycinforseveregrampositiveinfectionsapracticebasedstudy
AT mensajose factorsassociatedwithdevelopmentofnephrotoxicityinpatientstreatedwithvancomycinversusdaptomycinforseveregrampositiveinfectionsapracticebasedstudy
AT arteroarturo factorsassociatedwithdevelopmentofnephrotoxicityinpatientstreatedwithvancomycinversusdaptomycinforseveregrampositiveinfectionsapracticebasedstudy
AT epeldefrancisco factorsassociatedwithdevelopmentofnephrotoxicityinpatientstreatedwithvancomycinversusdaptomycinforseveregrampositiveinfectionsapracticebasedstudy
AT rodriguezjuancarlos factorsassociatedwithdevelopmentofnephrotoxicityinpatientstreatedwithvancomycinversusdaptomycinforseveregrampositiveinfectionsapracticebasedstudy
AT ruizmoralesjosefa factorsassociatedwithdevelopmentofnephrotoxicityinpatientstreatedwithvancomycinversusdaptomycinforseveregrampositiveinfectionsapracticebasedstudy
AT callejajoseluis factorsassociatedwithdevelopmentofnephrotoxicityinpatientstreatedwithvancomycinversusdaptomycinforseveregrampositiveinfectionsapracticebasedstudy
AT guerrajosemanuel factorsassociatedwithdevelopmentofnephrotoxicityinpatientstreatedwithvancomycinversusdaptomycinforseveregrampositiveinfectionsapracticebasedstudy
AT martinezgilinigo factorsassociatedwithdevelopmentofnephrotoxicityinpatientstreatedwithvancomycinversusdaptomycinforseveregrampositiveinfectionsapracticebasedstudy
AT gimenezmariajose factorsassociatedwithdevelopmentofnephrotoxicityinpatientstreatedwithvancomycinversusdaptomycinforseveregrampositiveinfectionsapracticebasedstudy
AT granizojuanjose factorsassociatedwithdevelopmentofnephrotoxicityinpatientstreatedwithvancomycinversusdaptomycinforseveregrampositiveinfectionsapracticebasedstudy
AT aguilarlorenzo factorsassociatedwithdevelopmentofnephrotoxicityinpatientstreatedwithvancomycinversusdaptomycinforseveregrampositiveinfectionsapracticebasedstudy